-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $31

Benzinga·05/19/2025 17:21:30
Listen to the news
Baird analyst Joel Beatty maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $28 to $31.